

Form PTO-1449 (modified)		Atty. Docket No. DFCI:005US	Serial No. 10/577,003
List of Patents and Publications for Applicant's		Applicant Surender KHARBANDA Donald W. KUFE	
INFORMATION DISCLOSURE STATEMENT		Filing Date: December 13, 2006	Group: 1643
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2004/0018181	01/29/04	Kufe <i>et al.</i>	424	93.21	05/29/03
	A2	5,380,712	01/10/95	Ballance <i>et al.</i>	514	12	02/14/92
	A3	5,766,883	06/16/98	Ballance and Goodey	435	69.7	11/17/93
	A4	5,965,386	10/12/99	Kerry-Williams <i>et al.</i>	435	69.1	03/01/95

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 00/25827	05/11/00	WIPO	English
	B2	WO 01/57068	08/09/01	WIPO	English
	B3	WO 03/088995	10/30/03	WIPO	English
	B4	WO 2004/044160	05/27/04	WIPO	English
	B5	WO 96/03502	02/08/96	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	"MUC-1/X mucin short variant," GenBank Accession No.: AAD10856, dated June 5, 2001
	C2	"MUC-1/Z mucin short variant," GenBank Accession No.: AAD10858, dated June 5, 2001.
	C3	"Mucin 1 precursor, non-repetitive splice from Y [validated] – human," GenBank Accession No.: S48146, dated April 20, 2000.
	C4	Backstrom <i>et al.</i> , "Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells," <i>Biochemical J.</i> , 376:677-686, 2003.
	C5	Barrett <i>et al.</i> , "PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?," <i>Int. J. Cancer</i> , 101:581-588, 2002.

25699980.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-J 449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No. DFCI:005US	Serial No. 10/577,003
List of Patents and Publications for Applicant's		Applicant Surender KHARBANDA Donald W. KUFE	
INFORMATION DISCLOSURE STATEMENT		Filing Date: December 13, 2006	Group: 1643
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C6	Baruch <i>et al.</i> , "Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function," <i>Int. J. Cancer</i> , 71:741-749, 1997.
	C7	Cunningham <i>et al.</i> , "Calreticulin binding and other biological activities of survival peptide Y-P30 including effects of systemic treatment of rats," <i>Exp. Neurol.</i> , 163:457-468, 2000.
	C8	Cunningham <i>et al.</i> , "Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin," <i>J. Neurosci.</i> , 18:7047-7060, 1998.
	C9	Cunningham <i>et al.</i> , "Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells," <i>Exp. Neurol.</i> , 177:32-39, 2002.
	C10	Elbashir <i>et al.</i> , "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213, 2002.
	C11	Gendler <i>et al.</i> , "A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats," <i>J Biol Chem</i> , 263:12820-12823, 1988.
	C12	Julian and Carson, "Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells," <i>Biochem. Biophys. Res. Commun.</i> , 293:1183-1190, 2002.
	C13	Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," <i>Hybridoma</i> , 3:223-232, 1984.
	C14	Li <i>et al.</i> , "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein," <i>Mol Cancer Res</i> , 1:765-775, 2003.
	C15	Li <i>et al.</i> , "Human DF3/MUC1 carcinoma-associated protein functions as an oncogene," <i>Oncogene</i> , 22:6107-6110, 2003.
	C16	Li <i>et al.</i> , "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin," <i>Mol Cell Biol</i> , 18:7216-7224, 1998.
	C17	Li <i>et al.</i> , "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin," <i>J Biol Chem</i> , 276:6061-6064, 2001.
	C18	Li <i>et al.</i> , "The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin," <i>J Biol Chem</i> , 276:35239-35242, 2001.
	C19	Ligtenberg <i>et al.</i> , "Suppression of cellular aggregation by high levels of episialin," <i>Cancer Res</i> , 52:2318-2324, 1992.

25699980.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No. DFCI:005US	Serial No. 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT		Applicant Surender KHARBANDA Donald W. KUFE	
(Use several sheets if necessary)		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Obermair <i>et al.</i> , "Expression of MUC1 splice variants in benign and malignant ovarian tumours," <i>Int. J. Cancer.</i> , 100:166-171, 2002.
	C21	Oosterkamp <i>et al.</i> , "Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z)," <i>Int. J. Cancer.</i> , 72:87-94, 1997.
	C22	Parry <i>et al.</i> , "Identification of MUC1 proteolytic cleavage sites in vivo," <i>Biochem. Biophys. Res. Commun.</i> , 283:715-720, 2001.
	C23	Porter <i>et al.</i> , "A neural survival factor is a candidate oncogene in breast cancer," <i>Proc. Natl. Acad. Sci. USA.</i> , 100:10931-10936, 2003.
	C24	Ren <i>et al.</i> , "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents," <i>Cancer Cell</i> , 5, 163-175, 2004.
	C25	Ren <i>et al.</i> , "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling," <i>J Biol Chem</i> , 277:17616-17622, 2002.
	C26	Schroeder <i>et al.</i> , "Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland," <i>J Biol Chem</i> , 276:13057-13064, 2001.
	C27	Siddiqui <i>et al.</i> , "Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen," <i>Proc Natl Acad Sci USA</i> , 85:2320-2323, 1988.
	C28	Yamamoto <i>et al.</i> , "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion," <i>J Biol Chem</i> , 272:12492-12494, 1997.
	C29	Yeh <i>et al.</i> , "Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate," <i>Proc. Natl. Acad. Sci. USA</i> , 89:1904-1908, 1992.
	C30	Zrihan-Licht <i>et al.</i> , "Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue," <i>Eur. J. Biochem.</i> , 224:787-795, 1994.

25699980.1

EXAMINER: /David Blanchard/

DATE CONSIDERED: 01/16/2009

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/